{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T09:40:05Z","timestamp":1756028405780,"version":"3.44.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,24]]},"DOI":"10.7759\/cureus.90860","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T09:26:18Z","timestamp":1756027578000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Non-muscle-Invasive Bladder Cancer"],"prefix":"10.7759","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Adomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Antonio De Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Banno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch MG","year":"2018","unstructured":"Cumberbatch MG, Jubber I, Black PC, et al.. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018, 74:784-95. 10.1016\/j.eururo.2018.09.001","journal-title":"Eur Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)36924-0","article-title":"Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group","volume":"148","author":"Prout GR Jr","year":"1992","unstructured":"Prout GR Jr, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol. 1992, 148:1413-9. 10.1016\/s0022-5347(17)36924-0","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester RJ","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, et al.. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006, 49:466-5. 10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys143","article-title":"Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection: Japan Clinical Oncology Group Study JCOG1019","volume":"42","author":"Kunieda F","year":"2012","unstructured":"Kunieda F, Kitamura H, Niwakawa M, et al.. Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection: Japan Clinical Oncology Group Study JCOG1019. Jpn J Clin Oncol. 2012, 42:1094-8. 10.1093\/jjco\/hys143","journal-title":"Jpn J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang SS","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, et al.. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016, 196:1021-9. 10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2015.12.011","article-title":"The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA)","volume":"13","author":"Inoue K","year":"2016","unstructured":"Inoue K, Matsuyama H, Fujimoto K, et al.. The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). Photodiagnosis Photodyn Ther. 2016, 13:91-6. 10.1016\/j.pdpdt.2015.12.011","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.07.007","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink M","year":"2013","unstructured":"Rink M, Babjuk M, Catto JW, et al.. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013, 64:624-38. 10.1016\/j.eururo.2013.07.007","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2021.06.011","article-title":"Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer","volume":"31","author":"Veeratterapillay R","year":"2021","unstructured":"Veeratterapillay R, Gravestock P, Nambiar A, et al.. Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer. Eur Urol Open Sci. 2021, 31:17-27. 10.1016\/j.euros.2021.06.011","journal-title":"Eur Urol Open Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15723","article-title":"Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review","volume":"130","author":"Maisch P","year":"2022","unstructured":"Maisch P, Koziarz A, Vajgrt J, Narayan V, Kim MH, Dahm P. Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review. BJU Int. 2022, 130:730-40. 10.1111\/bju.15723","journal-title":"BJU Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.02.009","article-title":"Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder","volume":"53","author":"Cowan ML","year":"2016","unstructured":"Cowan ML, Springer S, Nguyen D, et al.. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Hum Pathol. 2016, 53:8-13. 10.1016\/j.humpath.2016.02.009","journal-title":"Hum Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.53","article-title":"High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder","volume":"29","author":"Cowan M","year":"2016","unstructured":"Cowan M, Springer S, Nguyen D, et al.. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Mod Pathol. 2016, 29:511-5. 10.1038\/modpathol.2016.53","journal-title":"Mod Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela PJ","year":"2013","unstructured":"Killela PJ, Reitman ZJ, Jiao Y, et al.. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013, 110:6021-6. 10.1073\/pnas.1303607110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde I","year":"2013","unstructured":"Kinde I, Munari E, Faraj SF, et al.. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013, 73:7162-7. 10.1158\/0008-5472.CAN-13-2498","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1050","article-title":"TERT promoter mutations enhance telomerase activation by long-range chromatin interactions","volume":"6","author":"Min J","year":"2016","unstructured":"Min J, Shay JW. TERT promoter mutations enhance telomerase activation by long-range chromatin interactions. Cancer Discov. 2016, 6:1212-4. 10.1158\/2159-8290.CD-16-1050","journal-title":"Cancer Discov"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao0535","article-title":"Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism","volume":"357","author":"Chiba K","year":"2017","unstructured":"Chiba K, Lorbeer FK, Shain AH, et al.. Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science. 2017, 357:1416-20. 10.1126\/science.aao0535","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0276-y","article-title":"Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma","volume":"32","author":"Eich ML","year":"2019","unstructured":"Eich ML, Rodriguez Pena MD, Springer SU, et al.. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. Mod Pathol. 2019, 32:1544-50. 10.1038\/s41379-019-0276-y","journal-title":"Mod Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31935","article-title":"Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer","volume":"144","author":"Le\u00e3o R","year":"2019","unstructured":"Le\u00e3o R, Lee D, Figueiredo A, et al.. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2019, 144:1676-84. 10.1002\/ijc.31935","journal-title":"Int J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14000","article-title":"Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma","volume":"110","author":"Hayashi Y","year":"2019","unstructured":"Hayashi Y, Fujita K, Matsuzaki K, et al.. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Cancer Sci. 2019, 110:1771-9. 10.1111\/cas.14000","journal-title":"Cancer Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32143","article-title":"Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy","volume":"7","author":"Springer SU","year":"2018","unstructured":"Springer SU, Chen CH, Rodriguez Pena MD, et al.. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife. 2018, 7:10.7554\/eLife.32143","journal-title":"Elife"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12746","article-title":"TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer","volume":"14","author":"Hayashi Y","year":"2020","unstructured":"Hayashi Y, Fujita K, Nojima S, et al.. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Mol Oncol. 2020, 14:2375-83. 10.1002\/1878-0261.12746","journal-title":"Mol Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin MB","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al.. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging. CA Cancer J Clin. 2017, 67:93-9. 10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey PA","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016, 70:106-19. 10.1016\/j.eururo.2016.02.028","journal-title":"Eur Urol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21158-8","article-title":"Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer","volume":"12","author":"Hayashi Y","year":"2022","unstructured":"Hayashi Y, Fujita K, Sakai K, et al.. Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer. Sci Rep. 2022, 12:16642. 10.1038\/s41598-022-21158-8","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136416","article-title":"The utility of a flexible fluorescence-cystoscope with a twin mode monitor for the 5-aminolevulinic acid-mediated photodynamic diagnosis of bladder cancer","volume":"10","author":"Fukuhara H","year":"2015","unstructured":"Fukuhara H, Kureishi M, Khoda T, et al.. The utility of a flexible fluorescence-cystoscope with a twin mode monitor for the 5-aminolevulinic acid-mediated photodynamic diagnosis of bladder cancer. PLoS One. 2015, 10:e0136416. 10.1371\/journal.pone.0136416","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.09.037","article-title":"Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C intravesical therapy","volume":"57","author":"Draga RO","year":"2010","unstructured":"Draga RO, Grimbergen MC, Kok ET, Jonges TN, van Swol CF, Bosch JL. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C intravesical therapy. Eur Urol. 2010, 57:655-60. 10.1016\/j.eururo.2009.09.037","journal-title":"Eur Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000195537","article-title":"Cytogenetic analysis of false-positive mucosa by photodynamic diagnosis using 5-aminolevulinic acid - possible existence of premalignant genomic alterations examined by in vitro experiment","volume":"76","author":"Matsuyama H","year":"2009","unstructured":"Matsuyama H, Yamamoto Y, Nagao K, Ohmi C, Sakano S, Sasaki K. Cytogenetic analysis of false-positive mucosa by photodynamic diagnosis using 5-aminolevulinic acid - possible existence of premalignant genomic alterations examined by in vitro experiment. Oncology. 2009, 76:118-25. 10.1159\/000195537","journal-title":"Oncology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.10.015","article-title":"Mutational landscape of non-muscle-invasive bladder cancer","volume":"40","author":"Hurst CD","year":"2022","unstructured":"Hurst CD, Knowles MA. Mutational landscape of non-muscle-invasive bladder cancer. Urol Oncol. 2022, 40:295-303. 10.1016\/j.urolonc.2018.10.015","journal-title":"Urol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/387678-evaluation-of-telomerase-reverse-transcriptase-tert-promoter-mutations-in-photodynamic-diagnosis-with-5-aminolevulinic-acid-false-positive-sites-in-non-muscle-invasive-bladder-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T09:26:18Z","timestamp":1756027578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/387678-evaluation-of-telomerase-reverse-transcriptase-tert-promoter-mutations-in-photodynamic-diagnosis-with-5-aminolevulinic-acid-false-positive-sites-in-non-muscle-invasive-bladder-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,24]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.90860","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,24]]}}}